SEC Form 4 · accession 0001019687-15-003273
Sonoma Pharmaceuticals, Inc. · SNOA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert E Miller
Officer — Chief Financial Officer
Period of report
Aug 21, 2015
Accepted (ET)
Aug 25, 2015 · 8:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367083
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $1.16 | Aug 21, 2015 | A | 40,000 | A | — | Aug 21, 2025 | Common Stock | 40,000 | 308,041 | D |
Explanation of responses
- F1Options will only vest in whole or in part in the event the executive achieves a minimum of 80% of each of his Target Milestones in the fiscal year ending March 31, 2016 as determined by the Compensation Committee by June 30, 2016. If such executive does not achieve 80% of each of their Target Milestones, then 100% of the options will expire. If the executive achieves at least 80% of their Target Milestones by March 31, 2016, then 80% of the executive's options will vest on June 30, 2016. The vesting of the remaining 20% is in the discretion of the Compensation Committee and will vest on June 30, 2016, if at all.